glp-1 non responders Decoding the hallmarks of GLP-1RA weight-loss super Not losing weight on Ozempic,

95% CI 0.490.99)

Check if you can get discounts

TRIUMPH-4 (retatrutide, 68 weeks): Discontinuation due to AEs: 12.2% (9 mg), 18.2% (12 mg) vs 4.0% placebo Key characteristics: Highest GI adverse event rates among the drugs compared here Dysesthesia is a novel safety signal -- abnormal touch sensations affecting up to 21% at the 12 mg dose, not seen in Phase 2

IQVIA Payer Control Library Coverage Is Broader, but Friction Persists The relative success of diabetes GLP-1s is largely due to more favorable coverage and disease framing

The GLP-1 and hormones article covers how semaglutide interacts with female hormone systems more broadly, which is relevant context for women with PCOS planning their postpartum path

Mimicking the GLP-1 hormone triggers insulin release when your blood sugar is high